Cargando…

Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING)

BACKGROUND: Studies of flares of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination are limited by small sample size, short follow up or at risk of selection bias. METHODS: A national retrospective cohort study of consecutive AIIRD patients ≥12 years old, across 8 hos...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Margaret, Santosa, Amelia, Fong, Warren, Chew, Li-Ching, Low, Andrea HL, Law, Annie, Poh, Yih Jia, Yeo, Siaw Ing, Leung, Ying Ying, Ng, Victoria WW, Koh, Joshua ZE, Tay, Sen Hee, Mak, Anselm, Teng, Gim Gee, Xu, Chuanhui, Tang, Johnston GX, Kong, Kok Ooi, Angkodjojo, Stanley, Goh, Wei-Rui, Chuah, Tyng Yu, Roslan, Nur Emillia, Arkachaisri, Thaschawee, Teh, Kai Liang, Sriranganathan, Melonie, Tan, Teck Choon, Phang, Kee Fong, Yap, Qai Ven, Chan, Yiong Huak, Cheung, Peter PM, Lahiri, Manjari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705203/
https://www.ncbi.nlm.nih.gov/pubmed/36473406
http://dx.doi.org/10.1016/j.jaut.2022.102959
_version_ 1784840226823208960
author Ma, Margaret
Santosa, Amelia
Fong, Warren
Chew, Li-Ching
Low, Andrea HL
Law, Annie
Poh, Yih Jia
Yeo, Siaw Ing
Leung, Ying Ying
Ng, Victoria WW
Koh, Joshua ZE
Tay, Sen Hee
Mak, Anselm
Teng, Gim Gee
Xu, Chuanhui
Tang, Johnston GX
Kong, Kok Ooi
Angkodjojo, Stanley
Goh, Wei-Rui
Chuah, Tyng Yu
Roslan, Nur Emillia
Arkachaisri, Thaschawee
Teh, Kai Liang
Sriranganathan, Melonie
Tan, Teck Choon
Phang, Kee Fong
Yap, Qai Ven
Chan, Yiong Huak
Cheung, Peter PM
Lahiri, Manjari
author_facet Ma, Margaret
Santosa, Amelia
Fong, Warren
Chew, Li-Ching
Low, Andrea HL
Law, Annie
Poh, Yih Jia
Yeo, Siaw Ing
Leung, Ying Ying
Ng, Victoria WW
Koh, Joshua ZE
Tay, Sen Hee
Mak, Anselm
Teng, Gim Gee
Xu, Chuanhui
Tang, Johnston GX
Kong, Kok Ooi
Angkodjojo, Stanley
Goh, Wei-Rui
Chuah, Tyng Yu
Roslan, Nur Emillia
Arkachaisri, Thaschawee
Teh, Kai Liang
Sriranganathan, Melonie
Tan, Teck Choon
Phang, Kee Fong
Yap, Qai Ven
Chan, Yiong Huak
Cheung, Peter PM
Lahiri, Manjari
author_sort Ma, Margaret
collection PubMed
description BACKGROUND: Studies of flares of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination are limited by small sample size, short follow up or at risk of selection bias. METHODS: A national retrospective cohort study of consecutive AIIRD patients ≥12 years old, across 8 hospitals who received at least one dose of a COVID-19 mRNA vaccine. Patients were included from the date of 1st vaccine dose and censored at the time of flare or on the date of the clinic visit at least 3 months from cohort entry, whichever came first. Predictors of flare were determined by Cox proportional hazards analysis. FINDINGS: 4627 patients (73% Chinese, 71% female) of median (IQR) age 61 (48, 70) years were included; 42% Rheumatoid arthritis, 14% Systemic lupus erythematosus and 11% Psoriatic arthritis. 47% were in remission, 41% low disease activity, 10% moderate disease activity and 1% in high disease activity. 18% patients flared, of which 11.7% were within the 3-month period of interest. 11.8% patients improved. Median (IQR) time-to-flare was 60 (30, 114) days. 25% flares were self-limiting, 61% mild-moderate and 14% severe. Older patients (53–65 years and >66 years) had a lower risk of flare [HR 0.6 (95% CI 0.5–0.8) and 0.7 (0.6–0.8) respectively]. Patients with inflammatory arthritis and with active disease had a higher risk of flare [HR 1.5 (1.2–2.0) and 1.4 (1.2–1.6), respectively]. Treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), immunosuppression and prednisolone was also associated with an increased risk of flare [HR 1.5 (1.1–2), 1.2 (1.1–1.4) and 1.5 (1.2–1.8) for prednisolone ≤7.5 mg respectively]. INTERPRETATION: There was a moderately high rate of AIIRD flares after mRNA vaccination but also improvement in several patients. Severe flares and hospitalisation were rare. Thus, vaccination remains safe and highly recommended.
format Online
Article
Text
id pubmed-9705203
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Authors. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-97052032022-11-29 Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING) Ma, Margaret Santosa, Amelia Fong, Warren Chew, Li-Ching Low, Andrea HL Law, Annie Poh, Yih Jia Yeo, Siaw Ing Leung, Ying Ying Ng, Victoria WW Koh, Joshua ZE Tay, Sen Hee Mak, Anselm Teng, Gim Gee Xu, Chuanhui Tang, Johnston GX Kong, Kok Ooi Angkodjojo, Stanley Goh, Wei-Rui Chuah, Tyng Yu Roslan, Nur Emillia Arkachaisri, Thaschawee Teh, Kai Liang Sriranganathan, Melonie Tan, Teck Choon Phang, Kee Fong Yap, Qai Ven Chan, Yiong Huak Cheung, Peter PM Lahiri, Manjari J Autoimmun Article BACKGROUND: Studies of flares of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination are limited by small sample size, short follow up or at risk of selection bias. METHODS: A national retrospective cohort study of consecutive AIIRD patients ≥12 years old, across 8 hospitals who received at least one dose of a COVID-19 mRNA vaccine. Patients were included from the date of 1st vaccine dose and censored at the time of flare or on the date of the clinic visit at least 3 months from cohort entry, whichever came first. Predictors of flare were determined by Cox proportional hazards analysis. FINDINGS: 4627 patients (73% Chinese, 71% female) of median (IQR) age 61 (48, 70) years were included; 42% Rheumatoid arthritis, 14% Systemic lupus erythematosus and 11% Psoriatic arthritis. 47% were in remission, 41% low disease activity, 10% moderate disease activity and 1% in high disease activity. 18% patients flared, of which 11.7% were within the 3-month period of interest. 11.8% patients improved. Median (IQR) time-to-flare was 60 (30, 114) days. 25% flares were self-limiting, 61% mild-moderate and 14% severe. Older patients (53–65 years and >66 years) had a lower risk of flare [HR 0.6 (95% CI 0.5–0.8) and 0.7 (0.6–0.8) respectively]. Patients with inflammatory arthritis and with active disease had a higher risk of flare [HR 1.5 (1.2–2.0) and 1.4 (1.2–1.6), respectively]. Treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), immunosuppression and prednisolone was also associated with an increased risk of flare [HR 1.5 (1.1–2), 1.2 (1.1–1.4) and 1.5 (1.2–1.8) for prednisolone ≤7.5 mg respectively]. INTERPRETATION: There was a moderately high rate of AIIRD flares after mRNA vaccination but also improvement in several patients. Severe flares and hospitalisation were rare. Thus, vaccination remains safe and highly recommended. The Authors. Published by Elsevier Ltd. 2023-01 2022-11-29 /pmc/articles/PMC9705203/ /pubmed/36473406 http://dx.doi.org/10.1016/j.jaut.2022.102959 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Ma, Margaret
Santosa, Amelia
Fong, Warren
Chew, Li-Ching
Low, Andrea HL
Law, Annie
Poh, Yih Jia
Yeo, Siaw Ing
Leung, Ying Ying
Ng, Victoria WW
Koh, Joshua ZE
Tay, Sen Hee
Mak, Anselm
Teng, Gim Gee
Xu, Chuanhui
Tang, Johnston GX
Kong, Kok Ooi
Angkodjojo, Stanley
Goh, Wei-Rui
Chuah, Tyng Yu
Roslan, Nur Emillia
Arkachaisri, Thaschawee
Teh, Kai Liang
Sriranganathan, Melonie
Tan, Teck Choon
Phang, Kee Fong
Yap, Qai Ven
Chan, Yiong Huak
Cheung, Peter PM
Lahiri, Manjari
Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING)
title Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING)
title_full Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING)
title_fullStr Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING)
title_full_unstemmed Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING)
title_short Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING)
title_sort post-mrna vaccine flares in autoimmune inflammatory rheumatic diseases: results from the coronavirus national vaccine registry for immune diseases singapore (convin-sing)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705203/
https://www.ncbi.nlm.nih.gov/pubmed/36473406
http://dx.doi.org/10.1016/j.jaut.2022.102959
work_keys_str_mv AT mamargaret postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT santosaamelia postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT fongwarren postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT chewliching postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT lowandreahl postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT lawannie postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT pohyihjia postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT yeosiawing postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT leungyingying postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT ngvictoriaww postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT kohjoshuaze postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT taysenhee postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT makanselm postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT tenggimgee postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT xuchuanhui postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT tangjohnstongx postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT kongkokooi postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT angkodjojostanley postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT gohweirui postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT chuahtyngyu postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT roslannuremillia postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT arkachaisrithaschawee postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT tehkailiang postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT sriranganathanmelonie postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT tanteckchoon postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT phangkeefong postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT yapqaiven postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT chanyionghuak postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT cheungpeterpm postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing
AT lahirimanjari postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing